TY - JOUR T1 - Strontium ranelate reduced the risk of vertebral fractures in postmenopausal women with osteoporosis JF - Evidence Based Medicine JO - Evid Based Med SP - 149 LP - 149 DO - 10.1136/ebm.9.5.149 VL - 9 IS - 5 A2 - , Y1 - 2004/09/01 UR - http://ebm.bmj.com/content/9/5/149.abstract N2 - Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459–68.OpenUrlCrossRefPubMedWeb of Science 
 
 Q In postmenopausal women with osteoporosis, is strontium ranelate more effective than placebo for reducing the risk of vertebral fractures? Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Geriatrics ★★★★★☆☆ Rheumatology ★★★★★★☆ Design: randomised controlled trial. Allocation: unclear.* Blinding: blinded (patients and healthcare providers).* Follow up period: 3 years. Setting: 72 centres in 11 European countries and Australia. Patients: 1649 women who were ⩾50 years of age (mean age 69 y) and had been postmenopausal for ⩾5 years, had ⩾1 fracture confirmed by spinal radiography, and had a lumbar spine bone mineral density (BMD) ⩽0.840 g/cm2. Exclusion criteria were severe diseases or conditions that could interfere with bone metabolism or use of antiosteoporotic treatments (fluoride salts and bisphosphonates, oestrogen, calcitonin, or calcitriol). Intervention: all … ER -